Selected Publications

  1. Grover SA, Lowensteyn I, Karaouache M, Marchand S, Coupal L, DeCarolis E, Zoccoli J, Defoy I. The Prevalence of Erectile Dysfunction in the Primary Care Setting. Arch Intern Med. 2006;166:213-219. (Download PDF - 144KB)

  2. Dasgupta K, Grover SA, Da Costa D, Lowensteyn I, Yale JF,  Rahme E. Impact of modified glucose target and exercise interventions on vascular risk factors. Diabetes Research and Clinical Practice (2005) (Download PDF - 212KB)

  3. Da Costa D, Abrahamowicz M, Lowensteyn I, Bernatsky S,  Dritsa M, Fitzcharles MA, Dobkin PL. A randomized clinical trial of an individualized home-based exercise programme for women with fibromyalgia. Rheumatology 2005;44:1422–1427. (Download PDF - 108KB)

  4. Grover SA, Dorais M, Coupal L. Improving the prediction of cardiovascular risk: Interaction between LDL and HDL cholesterol. Epidemiol 2003;14;315-320. (Download PDF - 240KB)

  5. Grover SA, Ho V, Lavoie F, Coupal L, Zowall H, Pilote L. The importance of indirect costs in primary cardiovascular disease prevention: Can we save lives and money with statins? Arch Intern Med 2003;163:333-339. (Download PDF - 100KB)

  6. Lalonde L, Gray-Donald K, Lowensteyn I, Marchand S, Dorais M, Michaels G, Llewellyn-Thomas HA, O’Connor A, Grover SA, and The Canadian Collaborative Cardiac Assessment Group. Comparing the Benefits of Diet and Exercise in the Treatment of Dyslipidemia. Preventive Medicine 35, 16–24 (2002) (Download PDF - 208KB)

  7. Lalonde L, Clarke A, Joseph L, Mackenzie T, Grover SA and the Canadian Collaborative Cardiac Assessment Group. Health-related quality of life with coronary heart disease prevention and treatment. J Clin Epidemiol 2001;54:1011-1018. (Download PDF - 88KB)

  8. Grover SA, Coupal L, Zowall H, Alexander CM, Weiss TW, Gomes DRJ. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 2001;24:45-50. (Download PDF - 1200KB)

  9. Grover SA, Coupal L, Zowall H, Dorais M. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: Who should be treated? Circulation 2000;102:722-727. (Download PDF - 72KB)

  10. Grover SA, Coupal L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, Chetner M, Goldenberg L. The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. Can Med Assoc J 2000;162:987-92. (Download PDF - 220KB)

  11. Grover SA, Coupal L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, Chetner M, Goldenberg L. The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. Can Med Assoc J 2000;162:977-83. (Download PDF - 244KB)

  12. Lowensteyn I, Coupal L, Zowall H, Grover SA. The Cost-Effectiveness of Exercise Training for the Primary and Secondary Prevention of Cardiovascular Disease. Journal of Cardiopulmonary Rehabilitation 2000;20:147-155. (Download PDF - 100KB)

  13. Grover SA. Gambling with cardiovascular risk: Picking the winners and the losers. [Invited Editorial] The Lancet 1999;353:254-255. (Download PDF - 52KB)

  14. Lalonde L, Clarke AE, Joseph L, Grover SA and the Canadian Collaborative Cardiac Assessment Group. Conventional and chained standard gambles in the assessment of coronary heart disease prevention and treatment. Med Decis Making 1999;19:149-156. (Download PDF - 428KB)

  15. Lowensteyn I, Joseph L, Levinton C, Abrahamowicz M, Steinert Y, Grover. Can Computerized Risk Profiles Help Patients Improve Their Coronary Risk? The Results of The Coronary Health Assessment Study (CHAS). PREVENTIVE MEDICINE 27, 730–737 (1998) (Download PDF - 220KB)

  16. Grover SA, Paquet S, Levinton C, Coupal L, Zowall H. Estimating the benefits of modifying risk factors of cardiovascular disease: A comparison of primary vs secondary prevention. Arch Intern Med 1998;158:655-662. (Download PDF - 284KB)

  17. Lowensteyn I, Joseph L, Grover S. "Who Needs an Exercise Stress Test? Evaluating the New American College of Sports Medicine Risk Stratification Guidelines". Journal of Cardiopulmonary Rehabilitation, 1997; 17:253-260. (Download PDF - 72KB)
  18. Grover SA, Coupal L, Hu X-P. Identifying adults at increased risk of coronary disease: How well do the current cholesterol guidelines work? JAMA 1995;274:801-806. (Download PDF - 376KB)

  19. Grover SA, Lowensteyn I, Esrey KL, Steinert Y, Joseph L, Abrahamowicz M. Do doctors accurately assess coronary risk in their patients? Preliminary results of the Coronary Health Assessment Study (CHAS). BMJ 1995;310:975-978. (Download PDF - 220KB)

  20. Hamilton V, Racicot FE, Zowall H, Coupal L, Grover SA. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: Estimating the benefits of increasing HDL-C. JAMA 1995;273(13):1032-1038. (Download PDF - 452KB)

  21. Grover SA, Abrahamowicz M, Joseph L, Brewer C, Coupal L, Suissa S. The benefits of treating hyperlipidemia to prevent coronary heart disease: Estimating changes in life expectancy and morbidity. JAMA 1992;267(6):816-822. (Download PDF - 404KB

Quality data management when you need to know the truth

1303 Greene Avenue, Suite 500, Westmount, QC., H3Z 2A7
Tél. 514 846-7973 - Fax: 514 846-1447